Back to User profile » Dr Stefan Walzer
Papers published by Dr Stefan Walzer:
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Ponzetti C, Canciani M, Farina M, Era S, Walzer S
ClinicoEconomics and Outcomes Research 2017, 9:75-76
Published Date: 17 January 2017
Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach
Ponzetti C, Canciani M, Farina M, Era S, Walzer S
ClinicoEconomics and Outcomes Research 2016, 8:353-359
Published Date: 3 August 2016
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
Ponzetti C, Canciani M, Farina M, Era S, Walzer S
ClinicoEconomics and Outcomes Research 2016, 8:227-233
Published Date: 23 May 2016
Health economics evidence for medical nutrition: are these interventions value for money in integrated care?
Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H
ClinicoEconomics and Outcomes Research 2014, 6:241-252
Published Date: 19 May 2014
Health economic analyses in medical nutrition: a systematic literature review
Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H
ClinicoEconomics and Outcomes Research 2014, 6:109-124
Published Date: 10 March 2014
Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D
ClinicoEconomics and Outcomes Research 2013, 5:189-192
Published Date: 3 May 2013
Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:299-305
Published Date: 4 October 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:269-275
Published Date: 14 September 2012
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:237-243
Published Date: 3 September 2012